Dear Provider,

Due to the current increase in measles cases in the United States (https://www.cdc.gov/mmwr/volumes/68/wr/mm6817e1.htm), the Centers for Disease Control and Prevention has developed the following summary for vaccination of adults against measles with measles, mumps, rubella (MMR) vaccine. Recommendations for vaccination and assessing immunity in adults have not changed since publication of the Advisory Committee on Immunization Practices (ACIP) recommendations for the Prevention of Measles, Rubella, Congenital Rubella syndrome, and Mumps in June 2013. (https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6204a1.htm)

WHAT ADULT PROVIDERS NEED TO KNOW:

Providers do not need to actively screen adult patients for measles immunity.  This is because of high population immunity and low risk of disease among adults in non-outbreak areas in the U.S.

Providers should make sure patients have measles protection before international travel.  U.S. residents traveling internationally are at high risk for acquiring measles abroad.  They can also transmit measles to susceptible persons, such as infants, when they return home.

If a patient is traveling internationally and measles immunity is unknown, providers should vaccinate, unless there are contraindications.  Serologic testing for measles immunity is not recommended.

During outbreaks, providers should consult with local health departments for the most up-to-date recommendations for their community.  This may include additional doses of MMR for your patients.  

To download and print this letter in its entirety, click here.